A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

Status:
Completed

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

Patients will be assigned to one of three treatment groups. Study medication is administered over a 52 week study duration.

Phase 3

UCB Pharma

Certolizumab Pegol